RESEARCH & DEVELOPMENT

ZERO DAY TARGETS

We have leveraged the unique ability of our SuperHuman2.0 antibody discovery technology to generate thousands of best-in-class molecules against 26 critical immune oncology and neurodegeneration targets, enabling our partners to save years of research time.  By combining our AI-based Tumbler technology, we bioengineer an internal portfolio of antibodies to address uniquely challenging therapeutic opportunities.

ZERO DAY TARGETS

ANTIBODY

PANNING

UNIQUE HITS

SCREENING

PARTNERED

PD1

4406

2

LAG3

4304

1

GHR

8633

SIRPa

3630

CD47

5935

Glucagon

5204

GITR

5455

EphA3

6234

Transferrin

5298

TFR

ICOS

CD3e

cMET

4-1BB

OX40

VISTA

TIM-3

TIGIT

CTLA4

Amyloid beta

Tau

Alpha Synuclein

Beta secretase

 

MUC1

GET IN TOUCH

CONTACT US

(415) 489-0246

201 Gateway Blvd, Floor 1

 South San Francisco, CA 94080, USA